TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07687186: Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre With Reduced Ejection FrAction Resorted From Coronary Heart Disease (Syndrome of Qi Deficiency With Blood Stasis): A Phase 3 Randomized ControLled TrIal on

Sponsor: Tasly Pharmaceutical Group Co., Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 636 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,267,416

Rescue Site Savings

+$7,448,752

Unlock Full NCT07687186 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07687186 Rescue Dossier →